Dec 4,
2025 ACIP Comments Hepatitis B
Vaccine Toby Rogers
Transcript of my public comment at the ACIP meeting today:
Good afternoon. My name is Toby Rogers. I have a Ph.D. in Political
Economy from the University of Sydney and a Master of Public Policy
degree from UC Berkeley. I’m currently a Fellow at the Brownstone
Institute where I write about corruption in the pharmaceutical industry.
Using documents obtained via the Freedom of Information Act, the Informed
Consent Action Network demonstrated that the two most widely used
hepatitis B vaccines in the country Recombivax and Engerix never
should have been licensed by the FDA in the first place.
The clinical trials for Recombivax and Engerix:
• did not include a saline placebo control group;
• were too small to detect uncommon adverse events; and
• were too short to detect the majority of harms.
On that basis alone, Gold Standard Science requires that they be removed
from the market.
The autism rate in this country has skyrocketed since the introduction of
hepatitis B vaccines from 1 in 5,000 children diagnosed with autism in
the 1980s prior to the introduction of hepatitis B vaccines, to 1 in 31
children on the autism spectrum today.
A study by Thomas Verstraeten at the CDC’s Epidemic Intelligence Service
in 1999 showed that the birth dose of the hepatitis B vaccine increased
the relative risk of autism by more than eleven-fold. Soon thereafter Dr.
Verstraeten went to work for GSK in Belgium and the CDC has been covering
up his initial research findings ever since.
Vaccinated vs. unvaccinated studies by Gallagher and Goodman, published
in 2008 and 2010, also show that hepatitis B vaccines significantly
increase autism risk.
Hepatitis B vaccines have killed an astonishing number of children in the
U.S. over the last 35 years.
The Vaccine Adverse Events Reporting System contains 643 reports of death
of children and 52,281 total reports of harm, in the U.S., across all
ages, in connection with Recombivax and Engerix sh
Hepatitis B is also a component in many combination vaccines including
Pediarix and Vaxelis. The Vaccine Adverse Events Reporting System
contains 1,348 reports of death of children and 82,980 total reports of
harm in the U.S., across all ages, following combination hepatitis B
vaccines.
Remember that VAERS reports are a significant undercount of harms.
Respectfully, the proposed ACIP voting questions do not go far enough to
address documented safety problems. Moving the birth dose of hepatitis B
vaccine to 2 months would only produce a small reduction in autism and
SIDS rates. Combination shots are NOT safer. Moving the recommendation to
age 12 would be better, but would increase autoimmune disorders and POTS
cases in teenagers because of the high aluminum content in these shots.
The fact remains that there are NO data proving the safety and efficacy
of hepatitis B vaccines on day one, 2 months, or 12 years of age. Given
that, I believe that hepatitis B vaccines should be removed altogether
from the CDC childhood schedule.
·